NeuroBo Pharmaceuticals’ DA-1726 shows promising results in pre-clinical obesity treatment studies

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology firm, announced promising pre-clinical data for DA-1726, a novel oxyntomodulin (OXM) analog functioning as a dual agonist ... Read More